Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
23 hedge funds and large institutions have $139K invested in Navidea Biopharmaceuticals Inc. in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 12 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
23% less funds holding
Funds holding: 30 → 23 (-7)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
62% less capital invested
Capital invested by funds: $364K → $139K (-$226K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$62K |
| 2 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$20.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.1K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$6.38K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$6.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$62K |
| 2 |
Millennium Management
New York
|
-$33K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$26.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.1K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$7.29K |
NAVB Hedge Fund Activity: Q2 2023 in Review
23 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2023, worth a combined $139K — down 62% from $364K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NAVB and 5 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 9 added.
The largest buyer was State Street, adding an estimated $62K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $62K sold.
- 23 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $139K of Navidea Biopharmaceuticals Inc. stock for Q2 2023, down 62% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2023 and 12 closed out, a net change of -7 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2023 was State Street, an estimated $62K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2023 was Renaissance Technologies, an estimated $62K sold.
Based on aggregated 13F filings for Q2 2023.